NIH Pioneer Award Funds AI Scientist Engine to Accelerate Cancer Discovery

Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received an NIH Director’s Pioneer Award to build an artificial intelligence system designed to run the scientific process itself, from the first spark of a hypothesis to experimental validation, beginning with lung cancer. The award is part of the Common Fund’s High-Risk, High-Reward Research program, which supports scientists with outstanding records of creativity as they pursue pioneering approaches to major biomedical challenges. Only seven Pioneer Awards were issued this year, underscoring how selective the program is and how ambitious the proposed work must be to qualify. The honor carries a five-year grant of nearly $6 million, administered by the National Cancer Institute under grant DP1CA324880, and it will fund what Dr. Elemento describes as an AI-human discovery engine rather than a conventional research project.

The core idea is to pair large language model agents, the same class of AI systems that power tools like Claude or ChatGPT, with automated laboratory infrastructure capable of executing hundreds to thousands of experiments in parallel. Instead of relying on the published literature as its primary source of inspiration, the system will mine deidentified human data and molecular information from human cell and tissue samples to generate hypotheses about how cancer works. Those hypotheses will first be evaluated in computer modeling experiments using virtual tumors, AI models constructed from data on how real human cells respond when they are perturbed. Only after an idea survives simulation will it advance to physical testing on robotics platforms that manipulate human cells or organoids, the miniature three-dimensional tumors grown from patients’ own cells that have become a cornerstone of modern precision medicine.

Dr. Elemento argues that this architecture addresses two chronic weaknesses in how biomedical science is currently done. Previous efforts to build an AI scientist have concentrated on agents that read the scientific literature and propose hypotheses based on what has already been written. He considers those efforts valuable but fundamentally limited, because the literature is a secondhand and sometimes incomplete record of human biology, and an AI trained only on it can mostly recombine existing knowledge rather than surface genuinely new mechanisms. The second weakness is the traditional reliance on animal models tested one hypothesis at a time, a slow and expensive process whose results do not always translate to human patients. By grounding hypothesis generation in human data and testing many ideas simultaneously in human-derived systems, the discovery engine is designed to close both gaps at once.

The workflow he envisions is cyclical and self-correcting. AI agents propose biological mechanisms, the robotics platform tests them in parallel, and every round of experimental results is fed back into the AI, which learns from the outcomes and decides where the next experiments matter most. Virtual tumors serve as an intermediate filter, allowing the team to test an idea in simulation before committing laboratory resources to it. This iterative loop is what separates the project from simple prediction tools. As Dr. Elemento put it, prediction is not discovery; the goal is a system that proposes, tests and revises biological mechanisms the way scientists do, but at a scale and speed no human laboratory could match.

Human scientists remain firmly in the loop. Researchers will supervise the AI tools by setting research objectives, rejecting spurious hypotheses, and blocking experiments that are too costly or unlikely to succeed. They will also ensure that all work adheres to strict safety and ethical standards, a critical consideration for a system empowered to design and execute its own experiments on human-derived material. Dr. Elemento emphasized that the award will support the creation of an AI system to drive research from the initial data analysis through the validation stage, with human scientists’ oversight at every step, framing the technology as an amplifier of scientific judgment rather than a replacement for it.

The choice of lung cancer as the first target reflects the scale of unmet need. Patients with lung cancer currently face an overall five-year survival rate of fewer than 3 in 10, according to the American Cancer Society, and early-stage disease remains particularly difficult to manage. Dr. Elemento’s team will investigate why only some early lung lesions progress to invasive cancer, with particular attention to the hazy spots known as ground-glass opacities that appear on CT scans. By identifying the molecular and cellular changes that drive progression in these lesions, and by pinpointing where along that trajectory intervention might halt it, the researchers hope to open new therapeutic windows at the earliest and most treatable stages of the disease. As Dr. Elemento noted, there is a real need to discover new mechanisms that can be targeted pharmacologically, especially in the early stages of lung cancer.

The Englander Institute’s readiness for this challenge is no accident. Under Dr. Elemento’s leadership over the past five years, the institute has made major investments in data systems, data collection, robotics, and the development of disease models across many cancer types. Among these assets is a collection of more than 300 patient-derived organoid models spanning more than a dozen cancer types, a living library that gives the AI system an immediate and diverse testing ground. The institute has also assembled a very large dataset of information on the molecular and cellular features of lung cancer, which Dr. Elemento says now makes it possible to put everything together and let AI run the scientific process, with human oversight, in the hope of making major discoveries along the way.

Beyond lung cancer, the long-term ambition is to expand the platform to other types of cancer and, more broadly, to transform how science itself is conducted. Dr. Elemento envisions customizing AI agents for specific scientific roles, with separate agents specialized for hypothesis generation, critique, experimental design, or data analysis, each complementing the expertise of human scientists. Such specialized agents could analyze large, complex datasets that exceed human analytical capacity and enable the testing of personalized treatments tailored to individual tumors. He also wants to democratize access to these AI tools so that researchers without formal computer training can leverage them to advance and accelerate their own discoveries, spreading the benefits of automated experimentation far beyond institutions with deep computational resources.

The philosophical ambition underlying the project may be its most striking feature. For decades, Dr. Elemento observed, scientists have upgraded their instruments while keeping the same scientific method; this award, in his view, makes it possible to change the method itself. By entrusting part of the hypothesis-generation and testing cycle to AI agents that learn continuously from experimental outcomes, the program aims to establish a new AI-powered paradigm for research that makes large language models work for every scientist. If the discovery engine succeeds, the payoff could extend well beyond a single disease: a reusable, self-improving framework for biological discovery in which machines propose, robots test, and human researchers steer, all grounded in human data and validated in human-derived models. For a field where the path from observation to validated mechanism often takes years, compressing that cycle could reshape how the next generation of cancer therapies is found.

Subject of Research: An AI-driven discovery engine combining large language model agents, virtual tumor modeling and robotic organoid experiments to accelerate lung cancer research

Article Title: Dr. Olivier Elemento wins NIH Director’s Pioneer Award

Article References: Dr. Olivier Elemento wins NIH Director’s Pioneer Award. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NIH Director's Pioneer Award, Olivier Elemento, artificial intelligence, large language models, lung cancer, organoids, robotics, precision medicine, Weill Cornell Medicine, virtual tumors, high-risk high-reward research, cancer discovery